European Journal of Clinical Pharmacology

, Volume 21, Issue 5, pp 379–384 | Cite as

Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol

  • B. Hallengren
  • O. R. Nilsson
  • B. E. Karlberg
  • A. Melander
  • L. Tegler
  • E. Wåhlin-Boll
Originals

Summary

The kinetic profiles of oral methimazole 40mg, propranolol 80mg, metoprolol 100mg and atenolol 100mg were compared in hyperthyroid patients both during the hyper-and euthyroid states. For methimazole, neither the peak concentration (Cmax), the time to reach peak concentration (tmax), the elimination half-life (t1/2) nor the area under the curve (AUC) value was affected by the hyperthyroid state. For propranolol and metoprolol, which undergo extensive presystemic clearance, the AUC values were lower (p<0.02) when the patients were hyperthyroid than when they had become euthyroid, but the t1/2's were not significantly altered. For atenolol, there were no significant kinetic differences between the hyperthyroid and euthyroid states. The findings are compatible with the assumption that hyperthyroidism does not affect the kinetics of methimazole or atenolol, but that it may enhance presystemic clearance of propranolol and metoprolol.

Key words

hyperthyroidism propranolol methimazole metoprolol atenolol kinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeGroot LJ, Niepomniszcze H (1977) Biosynthesis of thyroid hormone: basic and clinical aspects. Metabolism 26: 665–718Google Scholar
  2. 2.
    Hallengren B, Forsgren A, Melander A (1980) Effects of antithyroid drugs on lymphocyte function in vitro. J Clin Endocrinol Metab 51:298–301Google Scholar
  3. 3.
    Nilsson O, Melander A, Tegler L (1980) Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients. Eur J Clin Pharmacol 18:315–320Google Scholar
  4. 4.
    Melander A, Hallengren B, Rosendal-Helgesen S, Sjöberg A-K, Wåhlin-Boll E (1980) Comparative in vitro effects and in vivo kinetics of antithyroid drugs. Eur J Clin Pharmacol 17:295–299Google Scholar
  5. 5.
    Skellern GG, Knight BI, Low CKL, Alexander WD, McLarty DG, Kalk WJ (1980) The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole in hyperthyroid patients. Br J Clin Pharmacol 19:137–143Google Scholar
  6. 6.
    Johnsson G, Regårdh C-G (1976) Clinical Pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacokinet 1:233–263Google Scholar
  7. 7.
    Nilsson OR, Karlberg BE, Kågedal B, Tegler L, Almqvist S (1979) Non-selective and selective β1-adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta Med Scand 206:21–25Google Scholar
  8. 8.
    Thorell JI, Larson SA (1978) Radioimmunoassay and related techniques. CV Mosby, St. Louis, MO, p 110Google Scholar
  9. 9.
    Gharib H, Ryan RJ, Mayberry WE, Hockert T (1971) Radioimmunoassay for triiodothyronine (T3): I Affinity and specificity of the antibody for T3. J Clin Endocrinol Metab 33:509–516Google Scholar
  10. 10.
    Seligson H, Seligson D (1972) Measurement of thyroxine by competitive protein binding. Clin Chim Acta 38:199–205Google Scholar
  11. 11.
    Melander A (1978) Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3:337–351Google Scholar
  12. 12.
    Skellern GG, Stenlake JB, Williams WD, McLarty DG (1974) Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients. Br J Clin Pharmacol 1:265–269Google Scholar
  13. 13.
    Pritchard JF, Schneck DW, Hayes Jr AH (1979) Determination of propranolol and six metabolities in human urine by highpressure liquid chromatography. J Chromatogr 162:47–58Google Scholar
  14. 14.
    Yee Y-G, Rubin P, Blaschke TF (1979) Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr 171:357–362Google Scholar
  15. 15.
    Ervik M (1975) Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol [Suppl] 36 (5):136–144Google Scholar
  16. 16.
    Eichelbaum M (1976) Drug metabolism in thyroid disease. Clin Pharmacokinet 1:339–350Google Scholar
  17. 17.
    Gilette JR (1965) Drug toxicity as a result of interference with physiological control mechanisms. Ann NY Acad Sci 123:42–54Google Scholar
  18. 18.
    Gordon GG, Southren AL, Tochimoto S, Rand JJ, Olivo J (1969) Effect of hyperthyroidism and hypothyroidism on the metabolite of testosterone and androstenedione in man. J Clin Endocrinol 29:164–170Google Scholar
  19. 19.
    Talseth T (1977) Clinical pharmacokinetics of hydrallazine. Clin Pharmacokinet 2:317–329Google Scholar
  20. 20.
    Feely J, Crooks J, Stevenson IH (1979) Altered pharmacokinetics of propranolol in hyperthyroidism. Br J Clin Pharmacol 8: 387 PGoogle Scholar
  21. 21.
    Riddell JG, Neill JD, Kelly JG, McDevitt DG (1980) Effects of thyroid dysfunction on propranolol kinetics. Clin Pharmacol Ther 28:565–574Google Scholar
  22. 22.
    Rubenfeld S, Silverman VE, Welch KMA, Mallette LE, Kohler PO (1978) Propranolol pharmacokinetics in thyrotoxicosis. Clin Res 26:295 AGoogle Scholar
  23. 23.
    Sitar DS, Abu-Bakare A, Gardiner RJ, Ogilvie RI (1979) Effect of chronic therapy with propylthiouracil on its disposition in hyperthyroid patients. Clin Invest Med 2:93–97Google Scholar
  24. 24.
    Forfar JC, Pottage A, Toft AD, Irvine WJ, Clements JA, Prescott LF (1980) Paracetamol pharmacokinetics in thyroid disease. Eur J Clin Pharmacol 18:269–273Google Scholar
  25. 25.
    Theilade P, Steiness E, Jørgensen PH, Hansen JM (1980) Decreased first-pass metabolism of propranolol in hyperthyroidism. World Conf Clin Pharmacol Ther, London, Abstract no.0608. Mac Millan, LondonGoogle Scholar
  26. 26.
    Marchant B, Lees FH, Alexander WD (1978) Antithyroid drugs. Pharmacol Ther [B] 3:305–348Google Scholar
  27. 27.
    Vesell ES, Shapiro JR, Passananti GT, Jorgensen H, Shively CA (1975) Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther 17:48–56Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • B. Hallengren
    • 1
    • 2
  • O. R. Nilsson
    • 1
    • 2
  • B. E. Karlberg
    • 1
    • 2
  • A. Melander
    • 1
    • 2
  • L. Tegler
    • 1
    • 2
  • E. Wåhlin-Boll
    • 1
    • 2
  1. 1.Departments of Endocrinology and Clinical PharmacologyLund University Clinics, Malmö General HospitalSweden
  2. 2.Department of Internal MedicineLinköping University HospitalLinköpingSweden

Personalised recommendations